Despite numerous treatment advances ... and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the excess HBsAg present in circulating virions, large amounts of ...

compared with none in the treatment group (24% vs 0%, respectively, P = 0.01 by log-rank). The results indicate that in recipients of HBsAg-positive marrow in HSCT, HBV-related hepatitis and ...

This is seen as a significant step forward in targeting HBsAg, a crucial antigen in hepatitis B treatment. Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio, remarked, “These data ...

A functional cure is said to have been achieved if HBsAg is cleared from the blood and remains undetectable after stopping all treatment. In B-Clear, patients with low baseline HBsAg levels ...

The therapy, which targets hepatitis B surface antigen (HBsAg), showed substantial antiviral ... The most common adverse events related to the treatment were consistent with the therapy's ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...